Form 4 for IONS IONIS PHARMACEUTICALS INC

Accepted 2025-02-03 00:00:00 ET · period of report 2025-01-30 · accession 0000874015-25-000079 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2025-02-03	2025-01-31	IONS	O'NEIL PATRICK R.	GC, EVP CLO	S - Sale	$32.49	-1,406	63.6K	-2%	-$45.7K
	2025-02-03	2025-01-30	IONS	O'NEIL PATRICK R.	GC, EVP CLO	A - Grant	$0.00	+3,820	65.0K	+6%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-01-31	S	D	1,406	$32.49	63,617	D	—	—	(F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.20 to $32.84 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
2	Common	Common Stock	2025-01-30	A	A	3,820	$0.00	65,023	D	—	—	(F1) Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the final performance period of the grant to the reporting person reported on January 19, 2022. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 150% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal.